AJMC® in the Press, April 17, 2020

An article by Nasdaq cited a study published in a supplement of The American Journal of Managed Care^® (AJMC^®) titled “The Economic Impact of Peanut Allergies.” The study indicated that peanut allergies affect an estimated 1.2% of the overall US population and about 2.5% of the pediatric population. The article noted that these patients could benefit from Aimmune Therapeutics’ treatment Palforzia, the first FDA-approved treatment for patients with peanut allergy.

A press release from UrgentMED Network, “UrgentMED Network Now Offering Telemedicine and Coronavirus Evaluations and Testing at Select Locations,” referenced a study published in the February 2015 issue of AJMC^®. The study, “Leveraging Remote Behavioral Health Interventions to Improve Medical Outcomes and Reduce Costs,” highlighted that successful patient engagement in a nationally available, remotely delivered behavioral health intervention can significantly improve medical outcomes and lower healthcare costs.

An article from AJMC^®’s sister site, The Center for Biosimilars^®, was featured in the April 15, 2020, daily Regulatory Recon news and intelligence briefing from Regulatory Focus. The article, “Merck Follows Rivals With US Launch of Trastuzumab Biosimilar,” was included in the In Focus: US section of the briefing and noted how Merck’s trastuzumab biosimilar Ontruzant marks the fifth trastuzumab biosimilar available on the US market.